Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MNKD NASDAQ:NVAX NASDAQ:XOMA NASDAQ:XOMAO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMNKDMannKind$3.70-0.8%$3.81$3.38▼$7.63$1.14B1.023.14 million shs2.17 million shsNVAXNovavax$9.43+6.6%$7.11$5.01▼$15.22$1.44B2.57.57 million shs8.73 million shsXOMAXOMA Royalty$31.59+2.3%$26.28$18.35▼$35.00$369.66M130,294 shs93,756 shsXOMAOXOMA$25.33-0.6%$25.41$23.32▼$25.87N/AN/A2,920 shs178 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMNKDMannKind-0.80%+7.87%-3.90%-15.33%-28.71%NVAXNovavax+6.55%+7.40%+37.06%+40.12%-22.64%XOMAXOMA Royalty+2.27%+22.25%+20.30%+17.04%+20.76%XOMAOXOMA-0.47%+0.45%-0.69%+1.10%+0.70%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMNKDMannKind3.0504 of 5 stars3.62.00.00.01.71.71.9NVAXNovavax4.6794 of 5 stars3.12.00.04.73.70.83.1XOMAXOMA Royalty4.4925 of 5 stars3.54.00.03.03.82.50.6XOMAOXOMAN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMNKDMannKind 3.25Buy$9.71162.55% UpsideNVAXNovavax 2.25Hold$15.8668.16% UpsideXOMAXOMA Royalty 3.00Buy$69.50120.01% UpsideXOMAOXOMA 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest XOMA, XOMAO, MNKD, and NVAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/7/2025MNKDMannKindRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$8.00 ➝ $7.007/23/2025MNKDMannKindRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$10.00 ➝ $8.007/22/2025NVAXNovavaxBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $9.007/16/2025MNKDMannKindHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$9.006/17/2025NVAXNovavaxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSell$6.005/28/2025XOMAXOMA RoyaltyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$104.005/19/2025NVAXNovavaxB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMNKDMannKind$285.50M3.98$0.14 per share26.88($0.18) per share-20.56NVAXNovavax$682.16M2.25N/AN/A$0.23 per share41.00XOMAXOMA Royalty$28.49M13.27N/AN/A$6.95 per share4.55XOMAOXOMA$13.05MN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMNKDMannKind$27.59M$0.1133.6416.09N/A10.87%-32.60%7.81%N/ANVAXNovavax-$187.50M$2.284.14117.880.1039.20%-142.33%28.65%N/AXOMAXOMA Royalty-$13.82M-$1.55N/AN/AN/A-27.57%2.54%0.97%N/AXOMAOXOMAN/AN/A0.00∞N/AN/AN/AN/AN/ALatest XOMA, XOMAO, MNKD, and NVAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025XOMAXOMA Royalty-$0.12$0.48+$0.60$0.44$9.39 million$13.13 million8/6/2025Q2 2025MNKDMannKind$0.04$0.05+$0.01N/A$77.82 million$76.53 million8/6/2025Q2 2025NVAXNovavax-$0.07$0.62+$0.69$0.62$149.19 million$239.24 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMNKDMannKindN/AN/AN/AN/AN/ANVAXNovavaxN/AN/AN/AN/AN/AXOMAXOMA RoyaltyN/AN/AN/AN/AN/AXOMAOXOMA$2.098.25%N/AN/AN/ALatest XOMA, XOMAO, MNKD, and NVAX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/21/2025XOMAOXOMAQuarterly$0.52348.28%7/3/20257/3/20257/15/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMNKDMannKindN/A2.502.24NVAXNovavax5.932.362.34XOMAXOMA Royalty1.185.545.54XOMAOXOMAN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMNKDMannKind49.55%NVAXNovavax53.04%XOMAXOMA Royalty95.92%XOMAOXOMAN/AInsider OwnershipCompanyInsider OwnershipMNKDMannKind2.70%NVAXNovavax1.00%XOMAXOMA Royalty9.10%XOMAOXOMAN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMNKDMannKind400306.83 million298.54 millionOptionableNVAXNovavax1,990162.42 million160.80 millionOptionableXOMAXOMA Royalty1011.97 million10.88 millionOptionableXOMAOXOMA10N/AN/ANot OptionableXOMA, XOMAO, MNKD, and NVAX HeadlinesRecent News About These CompaniesXOMA (NASDAQ:XOMAO) Trading Up 0.4% - Here's WhyAugust 14 at 3:27 AM | americanbankingnews.comXoma reports Q2 EPS 44c, consensus (15c)August 13 at 1:38 PM | msn.comXOMA Revenue Jumps 39% in Fiscal Q2August 13 at 1:38 PM | aol.comAXOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business AchievementsAugust 13 at 8:36 AM | finance.yahoo.comPharmalittle: We’re reading about Bill Gates’ women’s health pledge, a Vertex pain drug failure, and moreAugust 5, 2025 | statnews.comSPromise of gamma delta bispecific antibodies prompts XOMA acquisitionAugust 5, 2025 | thepharmaletter.comTXoma Royalty to Acquire Lava TherapeuticsAugust 4, 2025 | marketwatch.comHillevax Shares Gain on Acquisition Deal with XOMA RoyaltyAugust 4, 2025 | msn.comXoma Royalty to Acquire Lava Therapeutics, End Development of Lead CandidateAugust 4, 2025 | precisionmedicineonline.comPXoma strikes deals to buy struggling biotechs HilleVax, LavaAugust 4, 2025 | finance.yahoo.comXoma Royalty to Acquire HilleVaxAugust 4, 2025 | marketwatch.comXOMA Royalty to acquire cancer drug developer LAVA TherapeuticsAugust 4, 2025 | msn.comXoma Royalty to Acquire Lava Therapeutics -- UpdateAugust 4, 2025 | marketwatch.comXOMA Royalty (XOMA) Moves 9.0% Higher: Will This Strength Last? - NasdaqJune 26, 2025 | nasdaq.comWhy XOMA Royalty Corporation’s (XOMA) Stock Is Down 5.18%May 1, 2025 | aaii.comAXOMA Royalty Stock Dividends | NASDAQ:XOMAO | BenzingaApril 22, 2025 | benzinga.comXoma completes sale of Kinnate Pipeline assets for up to $270MApril 15, 2025 | markets.businessinsider.comBig moves by small biotechs signal potential shift for investorsApril 15, 2025 | bizjournals.comXOMA Royalty Corporation's (NASDAQ:XOMA) Path To ProfitabilityApril 15, 2025 | finance.yahoo.comThe Analyst Verdict: XOMA Royalty In The Eyes Of 4 ExpertsMarch 28, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeXOMA, XOMAO, MNKD, and NVAX Company DescriptionsMannKind NASDAQ:MNKD$3.70 -0.03 (-0.80%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$3.74 +0.04 (+1.19%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.Novavax NASDAQ:NVAX$9.43 +0.58 (+6.55%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$9.46 +0.04 (+0.37%) As of 04:40 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.XOMA Royalty NASDAQ:XOMA$31.59 +0.70 (+2.27%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$31.58 -0.01 (-0.03%) As of 08/14/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.XOMA NASDAQ:XOMAO$25.32 -0.15 (-0.57%) Closing price 08/14/2025 12:56 PM EasternExtended Trading$25.32 0.00 (0.00%) As of 08/14/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Deere’s Sell-Off Could Be a Long-Term Buying Chance Cisco Systems: The Only AI Stock Income Investors Need to Own Gartner’s RSI Just Sank to 11: That’s a Setup You Can’t Ignore How Did Peter Thiel-Backed Crypto Exchange Bullish's IPO Go? Mercury Systems Up 27%: Financials Send Investors a Clear Signal Brinker Serves Up Earnings Beat, Sidesteps Cost Pressures CAVA’s Honeymoon Ends With a 16% Stock Drop Rigetti Stock: A Long-Term Quantum Play Facing Short-Term Tests Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access